Companies/CN/002773

康弘药业 · CHENGDU KANGHONG PHARMACEUTICAL GROUP CO., LTD

Income flow

Annual
002773 10-K Income StatementPeriod 2025-12-31Source 10-K
Net salesCNY 5B+3% Y/YRevenueCNY 5B+3% Y/YGross profitCNY 4BCost of revenueCNY 465MOperating profitCNY 1BOperating expensesCNY 3BNet profitCNY 1BTaxCNY 211MSG&ACNY 2BR&D & otherCNY 1B

As-filed revenue segments and annual P&L (gross, opex, tax, net). Layout inspired by SankeyArt finance diagrams.

Revenue mix

2025-12-31 · 10-K · CNY
By activity
By activityCNY 4.6B
  • 生物药CNY 2.5B54.4%
  • 中成药CNY 1.5B32.6%
  • 化学药CNY 584M12.7%
  • 其他CNY 7M0.2%
  • 其他业务CNY 2M0.0%
By geography
By geographyCNY 4.6B
  • 华东CNY 1.2B27.0%
  • 华南CNY 1.1B24.9%
  • 西南CNY 834M18.2%
  • 华北CNY 607M13.2%
  • 西北CNY 411M9.0%
  • 东北CNY 352M7.7%
  • 境外CNY 478,8820.0%

Capital & dividends

YieldTrailing twelve-month dividends as a percent of the current share price (income yield).3.21%5y avgAverage dividend yield over the past five years — a smoother view than the latest print.0.97%Trailing DPSCash dividends paid per share over the last twelve months (dividend per share, trailing).0.7PayoutShare of earnings paid out as dividends. Higher means more income returned; lower leaves more for reinvestment.64.8%Shares outTotal shares currently outstanding (issued and not retired).921.3MFloatShares available to trade — outstanding minus closely held (insiders, strategic holders).280.3M
Dividend calendar
Ex-dividend
2026-06-09
Last cash
0.7 · 2026-06-09
Stock splits
  1. 1.3:12019-06-06

Valuation

Trailing PE 23.0 (2025-12-31)PE trend

Fiscal PE3

PeriodEPSClosePE
2025-12-311.2628.9523.0
2024-12-311.318.5614.3
2023-12-311.1415.1613.3

PE = stored close ÷ as-filed diluted EPS (annual 10-K / 20-F). Not a vendor PE series.